Bagsværd, Denmark - 25 September 2014 - Novo Nordisk will establish a new obesity research unit in Seattle, Washington, USA. The main task of the unit will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets.
"Our ambition is to drive scientific progress in the obesity disease area and through this identify and develop new treatment options for people with obesity", said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk.
Dr Kevin Grove has accepted the position as head of the Novo Nordisk Obesity Research Unit in Seattle. Grove is a renowned expert in endocrinology specialising in obesity and health-related quality of life, and joins Novo Nordisk from a position as senior scientist at the Oregon Health & Science University, and founding division chief, Division of Diabetes, Obesity & Metabolism.
The Novo Nordisk Obesity Research Unit will initially employ around 10 people, supported by the current obesity research and corporate functions. When fully operational by the end of 2016, the unit is expected to employ around 60 employees. Globally, around 300 employees are working within obesity research and development at Novo Nordisk.
The Obesity Research Unit will be co-located with the Novo Nordisk Type 1 Diabetes Research Unit at the company's research centre in Seattle, which opened in 2009.
Headquartered in Denmark, Novo Nordisk is a global healthcare company. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.
Source: Novo Nordisk